blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1556398

EP1556398 - NOVEL CYTARABINE MONOPHOSPHATE PRODRUGS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  16.07.2010
Database last updated on 22.08.2024
Most recent event   Tooltip30.09.2011Lapse of the patent in a contracting state
New state(s): TR		published on 02.11.2011  [2011/44]
Applicant(s)For all designated states
Metabasis Therapeutics, Inc.
11119 North Torrey Pines Road
La Jolla CA 92037 / US
[2006/02]
Former [2005/30]For all designated states
Metabasis Therapeutics, Inc.
9390 Towne Centre Drive
San Diego, CA 92121 / US
Inventor(s)01 / BOYER, Serge H.
5112 Castle Hills Drive
San Diego, CA 92109 / US
02 / ERION, Mark D.
13455 Mango Drive
Del Mar, CA 92014 / US
 [2005/30]
Representative(s)Wiegeleben, Peter
Uexküll & Stolberg Partnerschaft von
Patent- und Rechtsanwälten mbB
Beselerstrasse 4
22607 Hamburg / DE
[N/P]
Former [2009/21]Wiegeleben, Peter
Uexküll & Stolberg Patentanwälte Beselerstrasse 4
22607 Hamburg / DE
Former [2005/30]Sexton, Jane Helen
J.A. KEMP & CO. 14 South Square Gray's Inn
London WC1R 5JJ / GB
Application number, filing date03778030.131.10.2003
[2005/30]
WO2003US34690
Priority number, dateUS20020423259P31.10.2002         Original published format: US 423259 P
US20020423211P31.10.2002         Original published format: US 423211 P
[2005/30]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2004041837
Date:21.05.2004
Language:EN
[2004/21]
Type: A1 Application with search report 
No.:EP1556398
Date:27.07.2005
Language:EN
The application published by WIPO in one of the EPO official languages on 21.05.2004 takes the place of the publication of the European patent application.
[2005/30]
Type: B1 Patent specification 
No.:EP1556398
Date:09.09.2009
Language:EN
[2009/37]
Search report(s)International search report - published on:EP21.05.2004
ClassificationIPC:C07H19/10, A61K31/7068, A61P35/00
[2005/30]
CPC:
C07F9/65742 (EP,US); C07H19/10 (KR); A61P31/12 (EP);
A61P35/00 (EP); A61P43/00 (EP); C07H19/04 (EP,US)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   RO,   SE,   SI,   SK,   TR [2005/30]
Extension statesALNot yet paid
LTNot yet paid
LVNot yet paid
MKNot yet paid
TitleGerman:CYTARABIN-MONOPHOSPHATE PRODRUGS[2005/30]
English:NOVEL CYTARABINE MONOPHOSPHATE PRODRUGS[2005/30]
French:NOUVEAUX PROMEDICAMENTS DE CYTARABINE MONOPHOSPHATE[2005/30]
Entry into regional phase28.04.2005National basic fee paid 
28.04.2005Designation fee(s) paid 
28.04.2005Examination fee paid 
Examination procedure30.04.2004Request for preliminary examination filed
International Preliminary Examining Authority: EP
28.04.2005Examination requested  [2005/30]
24.07.2006Despatch of a communication from the examining division (Time limit: M06)
31.01.2007Reply to a communication from the examining division
10.02.2009Communication of intention to grant the patent
22.06.2009Fee for grant paid
22.06.2009Fee for publishing/printing paid
Opposition(s)10.06.2010No opposition filed within time limit [2010/33]
Fees paidRenewal fee
27.10.2005Renewal fee patent year 03
27.10.2006Renewal fee patent year 04
29.10.2007Renewal fee patent year 05
27.10.2008Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT09.09.2009
BE09.09.2009
CY09.09.2009
CZ09.09.2009
DK09.09.2009
EE09.09.2009
FI09.09.2009
IT09.09.2009
NL09.09.2009
RO09.09.2009
SE09.09.2009
SI09.09.2009
SK09.09.2009
TR09.09.2009
BG31.10.2009
CH31.10.2009
IE31.10.2009
LI31.10.2009
LU31.10.2009
MC31.10.2009
GR10.12.2009
ES20.12.2009
PT11.01.2010
HU10.03.2010
[2011/44]
Former [2011/31]AT09.09.2009
BE09.09.2009
CY09.09.2009
CZ09.09.2009
DK09.09.2009
EE09.09.2009
FI09.09.2009
IT09.09.2009
NL09.09.2009
RO09.09.2009
SE09.09.2009
SI09.09.2009
SK09.09.2009
BG31.10.2009
CH31.10.2009
IE31.10.2009
LI31.10.2009
LU31.10.2009
MC31.10.2009
GR10.12.2009
ES20.12.2009
PT11.01.2010
HU10.03.2010
Former [2011/21]AT09.09.2009
BE09.09.2009
CY09.09.2009
CZ09.09.2009
DK09.09.2009
EE09.09.2009
FI09.09.2009
IT09.09.2009
NL09.09.2009
RO09.09.2009
SE09.09.2009
SI09.09.2009
SK09.09.2009
BG31.10.2009
CH31.10.2009
IE31.10.2009
LI31.10.2009
LU31.10.2009
MC31.10.2009
GR10.12.2009
ES20.12.2009
PT11.01.2010
Former [2011/14]AT09.09.2009
BE09.09.2009
CY09.09.2009
CZ09.09.2009
DK09.09.2009
EE09.09.2009
FI09.09.2009
IT09.09.2009
NL09.09.2009
RO09.09.2009
SE09.09.2009
SI09.09.2009
SK09.09.2009
BG31.10.2009
CH31.10.2009
IE31.10.2009
LI31.10.2009
MC31.10.2009
GR10.12.2009
ES20.12.2009
PT11.01.2010
Former [2010/46]AT09.09.2009
BE09.09.2009
CY09.09.2009
CZ09.09.2009
DK09.09.2009
EE09.09.2009
FI09.09.2009
NL09.09.2009
RO09.09.2009
SE09.09.2009
SI09.09.2009
SK09.09.2009
CH31.10.2009
IE31.10.2009
LI31.10.2009
MC31.10.2009
GR10.12.2009
ES20.12.2009
PT11.01.2010
Former [2010/35]AT09.09.2009
BE09.09.2009
CY09.09.2009
CZ09.09.2009
DK09.09.2009
EE09.09.2009
FI09.09.2009
NL09.09.2009
RO09.09.2009
SE09.09.2009
SI09.09.2009
SK09.09.2009
MC31.10.2009
ES20.12.2009
PT11.01.2010
Former [2010/30]AT09.09.2009
BE09.09.2009
CY09.09.2009
CZ09.09.2009
EE09.09.2009
FI09.09.2009
NL09.09.2009
RO09.09.2009
SE09.09.2009
SI09.09.2009
SK09.09.2009
MC31.10.2009
ES20.12.2009
PT11.01.2010
Former [2010/28]BE09.09.2009
CY09.09.2009
CZ09.09.2009
EE09.09.2009
FI09.09.2009
NL09.09.2009
RO09.09.2009
SE09.09.2009
SI09.09.2009
SK09.09.2009
MC31.10.2009
ES20.12.2009
PT11.01.2010
Former [2010/25]CY09.09.2009
CZ09.09.2009
EE09.09.2009
FI09.09.2009
NL09.09.2009
RO09.09.2009
SE09.09.2009
SI09.09.2009
SK09.09.2009
MC31.10.2009
ES20.12.2009
PT11.01.2010
Former [2010/23]CY09.09.2009
CZ09.09.2009
EE09.09.2009
FI09.09.2009
NL09.09.2009
RO09.09.2009
SE09.09.2009
SI09.09.2009
SK09.09.2009
ES20.12.2009
PT11.01.2010
Former [2010/22]CY09.09.2009
CZ09.09.2009
EE09.09.2009
FI09.09.2009
NL09.09.2009
RO09.09.2009
SE09.09.2009
SI09.09.2009
ES20.12.2009
PT11.01.2010
Former [2010/20]CY09.09.2009
EE09.09.2009
FI09.09.2009
NL09.09.2009
SE09.09.2009
SI09.09.2009
ES20.12.2009
Former [2010/19]CY09.09.2009
FI09.09.2009
NL09.09.2009
SE09.09.2009
SI09.09.2009
ES20.12.2009
Former [2010/16]CY09.09.2009
FI09.09.2009
NL09.09.2009
SE09.09.2009
SI09.09.2009
Former [2010/11]FI09.09.2009
NL09.09.2009
SE09.09.2009
SI09.09.2009
Former [2010/10]FI09.09.2009
NL09.09.2009
SE09.09.2009
Former [2010/09]FI09.09.2009
SE09.09.2009
Cited inInternational search[X]US6312662  (ERION MARK D [US], et al) [X] 1-19* column 30 line 53- column 31 line 3 column 42 lines 18-64 columns 56-57 claims *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.